Page 5 - e-CPG-SLE-8_5_24

Management of Systemic Lupus Erythematosus

TABLE OF CONTENTS

No. Title Page
9. MONITORING 30
9.1 Clinical Features 30
9.2 Laboratory Investigations 30
9.3 Co-morbidities 31
9.4 Drug Adverse Events 33
9.5 Frequency and Interval 34
10. SPECIAL CONSIDERATION 35
10.1 Antiphospholipid Syndrome 35
10.2 Pregnancy 36
10.3 Lactation 40
10.4 Adolescents 40
10.5 Vaccination 41

11. REFERRAL 43

12. IMPLEMENTING THE GUIDELINES 44
12.1 Facilitating and Limiting Factors 44
12.2 Potential Resource Implication 44

REFERENCES 46

Appendix 1 Example of Search Strategy 54
Appendix 2 Clinical Questions 55
Appendix 3 2012 SLICC Classification Criteria for SLE 57
Appendix 4 2019 EULAR/ACR Classification Criteria 59
for SLE
Appendix 5 Systemic Lupus Erythematosus Disease 60
Activity Index - 2000 (SLEDAI-2K)
Appendix 6 British Isles Lupus Activity Group (BILAG) 62
Index - 2004
Appendix 7 Medication in SLE 64
Appendix 8 Frequency of Monitoring Patients with SLE 70
Appendix 9 Sapporo Classification Criteria 72
Appendix 10 Recommendations on Types of 74
Contraception for Patients with SLE

List of Abbreviations 79
Acknowledgement 79
Disclosure Statement 79
Source of Funding 79